肾衰竭成人CKD相关骨质疏松的治疗机会提示需筛查
单中心邀请203例透析患者(>50岁或绝经后),121例符合条件,71例完成包含DXA的综合骨健康评估。73%存在CKD相关骨质疏松,仅21%接受骨靶向治疗,提示综合评估可揭示多种治疗机会。
要点
- 73%的肾衰竭患者存在CKD相关骨质疏松。
- 仅21%的CKD相关骨质疏松患者接受骨靶向治疗。
- 综合骨健康评估可发现 mineral metabolism、非药物和药物干预机会。
核心结论
- 综合骨健康评估在7/10的肾衰竭患者中识别出CKD相关骨质疏松,并揭示从优化矿物质代谢到非药物和药物骨靶向干预的多种治疗机会。
研究设计与样本
- 单中心研究,邀请所有年龄>50岁或绝经后、预期寿命>1年的透析患者参与综合骨健康评估。
- 203例患者筛查,121例符合条件,其中71例完成包括DXA的综合表型评估。
主要发现
- 73%的参与者存在CKD相关骨质疏松,基于髋部或腰椎T值≤-2.5(65%)、脆性骨折史(41%)和/或椎体骨折(13%)。
- 维生素D不足(<30 ng/mL)和钙摄入不足(<800 mg/day)分别见于35%和29%的患者。
- 尽管仅17%的患者bio-intact PTH超过KDIGO目标范围,但53%的患者骨转换标志物提示高骨转换。
- 65%的患者握力低于肌少症阈值,55%的患者体力活动水平低。
- 仅21%的CKD相关骨质疏松患者接受骨靶向治疗。
临床怎么用
- 对肾衰竭患者应开展综合骨健康评估以识别CKD相关骨质疏松。
- 评估内容包括风险因素、钙摄入、矿物质代谢参数、骨转换标志物、骨折史、DXA骨密度和椎体骨折、握力及体力活动。
- 根据评估结果可优化矿物质代谢、增加非药物干预(如营养、运动)并考虑骨靶向药物治疗。
局限性
- 单中心研究,结果需反思和确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fracture risk in patients with chronic kidney disease (CKD) is excessively high. A recent European consensus provides guidance on the comprehensive screening for CKD-associated osteoporosis in patients with CKD stages G4-5D. However, data on the yield and therapeutic implications of this approach in patients with kidney failure is lacking. METHODS: All prevalent dialysis patients aged >50 years or postmenopausal with life expectancy >1 year at a single center were invited for comprehensive bone health assessment, including the evaluation of risk factors, calcium intake, mineral metabolism parameters, bone turnover markers, fracture history, bone mineral density and vertebral fractures by dual-energy X-ray absorptiometry (DXA), handgrip strength and self-reported physical activity. RESULTS: Of 203 patients screened, 121 (mean age 75 years, 55% male) were eligible, of whom 71 underwent comprehensive phenotyping including DXA. CKD-associated osteoporosis was identified in 73% of participants, based on a T-score ≤-2.5 at the hip or lumbar spine (65%), history of fragility fracture (41%) and/or finding of a vertebral fracture (13%). Vitamin D insufficiency (<30 ng/mL) and insufficient calcium intake (<800 mg/day) were observed in 35% and 29%, respectively. Despite bio-intact parathyroid hormone levels exceeding the KDIGO target range in only 17%, bone turnover markers suggested high bone turnover in 53% of patients. Handgrip strength was below sarcopenia threshold in 65%, while physical activity was low in 55% of participants. Only 21% of patients with CKD-associated osteoporosis were treated with bone targeting therapy. CONCLUSION: Comprehensive bone health assessment identified CKD-associated osteoporosis in 7 out of 10 patients with kidney failure and unveiled several therapeutic opportunities ranging from optimization of mineral metabolism to non-pharmacological and pharmacological bone-targeting interventions. The present single-center findings call for reflection and confirmation.
引用
- Engelen T, Smout D, Laurent MR, et al. Therapeutic opportunities for CKD-associated osteoporosis in adults with kidney failure imply screening. Nephrol Dial Transplant. 2026. PMID: 41733465. doi:10.1093/ndt/gfag038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。